Cargando…
"The metabolic syndrome... is dead": These reports are an exaggeration
The debates continue over the validity of the metabolic syndrome concept. The continuous increment of the obesity pandemic is almost worldwide paralleled by rising rates of metabolic syndrome prevalence. Then, it seems obvious that these debates drove the need for further investigations as well as a...
Autores principales: | Tenenbaum, Alexander, Fisman, Enrique Z |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036609/ https://www.ncbi.nlm.nih.gov/pubmed/21269524 http://dx.doi.org/10.1186/1475-2840-10-11 |
Ejemplares similares
-
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
por: Tenenbaum, Alexander, et al.
Publicado: (2004) -
Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?
por: Fisman, Enrique Z, et al.
Publicado: (2014) -
The ubiquitous interleukin-6: a time for reappraisal
por: Fisman, Enrique Z, et al.
Publicado: (2010) -
Statins research unfinished saga: desirability versus feasibility
por: Fisman, Enrique Z, et al.
Publicado: (2005) -
Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)
por: Tenenbaum, Alexander, et al.
Publicado: (2003)